We rank companies based on fund manager, research analyst and news sentiment
GOSS stock icon

Gossamer Bio
GOSS

$0.82
2.5%
 

About: Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Employees: 135

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 8 analysts
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

39% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 23

12% more capital invested

Capital invested by funds: $171M [Q3] → $193M (+$21.4M) [Q4]

11% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 19

2% more funds holding

Funds holding: 93 [Q3] → 95 (+2) [Q4]

1.88% more ownership

Funds ownership: 91.22% [Q3] → 93.1% (+1.88%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

38% less call options, than puts

Call options by funds: $367K | Put options by funds: $590K

Research analyst outlook

8 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$4
388%
upside
Avg. target
$8.13
891%
upside
High target
$15
1,729%
upside

8 analyst ratings

positive
100%
neutral
0%
negative
0%
Wedbush
Laura Chico
388%upside
$4
Outperform
Assumed
5 Apr 2024
Piper Sandler
Yasmeen Rahimi
1,729%upside
$15
Overweight
Maintained
27 Mar 2024
Goldman Sachs
Paul Choi
876%upside
$8
Buy
Maintained
6 Mar 2024
Wedbush
Andreas Argyrides
632%upside
$6
Outperform
Reiterated
6 Mar 2024
HC Wainwright & Co.
Patrick Trucchio
1,120%upside
$10
Buy
Reiterated
6 Mar 2024

Financial journalist opinion